Credit Suisse Reiterates Outperform, $156 Target On Johnson & Johnson As Firm Notes Co. 'appears to be tracking ahead of our Q3 US Pharma estimates, based on our updated analysis of intra-quarter scrips and IMS-reported sales trends for both July and Aug'